Printer Friendly

NVIDIA® Graphics Power Groundbreaking Cancer-Detection Solution

 
 

Product PR:

Luciano Alibrandi
Director of Product PR EMEA
Tel: +33 1 55 63 84 92
lalibrandi@nvidia.com

FOR IMMEDIATE RELEASE

NVIDIA® Graphics Power Groundbreaking Cancer-Detection Solution

DBT System Developed by Mass General Hospital and Mercury Computer Receives "Imaging Solutions of The Year" Award

BANGALORE, INDIA-FEBRUARY 21, 2006-NVIDIA Corporation (NASDAQ: NVDA) today announced that a groundbreaking cancer-detection system, developed by Massachusetts General Hospital and Mercury Computer Systems, has been recognised by Advanced Imaging Magazine with an "Imaging Solutions of the Year" award. NVIDIA Quadro® FX professional graphics solutions provide the processing power for the computationally-intense system.

Award winners were chosen based on the uniqueness of the challenge as well as on the creativity of their solution. Categories covered the spectrum -- from industrial and machine vision through space imaging and image visualisation to medical, microscopy, military and commercial applications.

Massachusetts General Hospital developed the Digital Breast Tomosynthesis (DBT) imaging system and Mercury Computer Systems developed a high-speed solution to permit rapid processing of the images. NVIDIA Quadro FX includes a unique programmable rendering pipeline that enables the reconstruction of a 3D volume from a series of 2D projection images.

"This award is a significant achievement in our collaboration with Mass General Hospital to improve cancer detection and diagnosis," said Marcelo Lima, vice president of Commercial Imaging and Visualisation at Mercury Computer Systems. "With NVIDIA technology, we hope to take this promising DBT imaging technique from the laboratory to widespread clinical use."

Components of the system also include the Senographe 2000 Digital Mammography System from GE Healthcare and an advanced "likelihood expectation" algorithm co-developed by Brandeis University and Massachusetts General Hospital. The project was supported in part by two grants from the US Army Medical Research and Material Command.

DBT provides the advantage of enabling physicians to "page through" the interior of the breast without obstruction by surrounding superimposed tissue. In the past, the potential benefits of DBT were downplayed because the method was computationally intense and took far too long for use in a clinical setting. With the new system, computation time was reduced from five hours to five minutes, a 60x performance increase. In pre-clinical testing, the new DBT system permitted physicians to find cancers earlier and more easily, and to differentiate benign versus malignant lesions while simultaneously reducing false positives.

Advanced Imaging is dedicated to providing the latest information on imaging hardware, software and peripherals to qualified professionals working with all forms of electronic imaging. For more information on the "Imaging Solutions of the Year" awards, go to: http://www.advancedimagingpro.com/publication/article.jsp?pubId=1&id=2327

About NVIDIA
NVIDIA Corporation is a worldwide leader in graphics and digital media processors. The Company’s products enhance the end-user experience on consumer and professional computing devices. NVIDIA graphics processing units (GPUs), media and communications processors (MCPs), and wireless media processors (WMPs) have broad market reach and are incorporated into a variety of platforms, including consumer and enterprise PCs, notebooks, workstations, PDAs, mobile phones, and video game consoles. NVIDIA is headquartered in Santa Clara, California and employs more than 2,000 people worldwide. For more information, visit the Company’s Web site at www.nvidia.in.

Certain statements in this press release including, but not limited to, statements as to our relationships with customers and partners in the film industry and the features, benefits, performance and capability of the NVIDIA Quadro FX are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Such risks and uncertainties include, but are not limited to, delays in ramping new products into production, adoption of other technologies or products by those in the film industry, manufacturing defects, incompatibility of technologies, reliance on third-party manufacturers, the impact of competitive products and pricing alternatives, n changes in the film industry standards, our dependence on third-party developers and other risks detailed from time to time in the NVIDIA reports filed with the Securities and Exchange Commission including its Form 10-Q for the quarter ended October 24, 2004. These forward-looking statements speak only as of the date hereof. NVIDIA disclaims any obligation to update these forward-looking statements.

# # #

Copyright © 2005 NVIDIA Corporation. All rights reserved. All company and/or product names may be trade names, trademarks and/or registered trademarks of the respective owners with which they are associated. Features, pricing, availability, and specifications are subject to change without notice.

Note to editors: If you are interested in viewing additional information on NVIDIA, please visit the NVIDIA Press Room.



 
 
FacebookTwitterLinkedInGoogle+Pinterest